Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ZVRA vs SANA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ZVRA Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

ZVRA Overall Winner 6-Pillar Tally: ZVRA 5 – 1 SANA Matrix Metrics: ZVRA 8 – 2 SANA

As of Nov 16, 2026, Zevra Therapeutics, Inc. (ZVRA) is the stronger overall head-to-head candidate over Sana Biotechnology, Inc. (SANA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZVRA carries a Unified Composite Score of 49.4/100 (HOLD) at $9.25 (10.4x Forward P/E, 31.5% operating margin), whereas SANA carries 44.3/100 (HOLD) at $1.88 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: ZVRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.9); meanwhile SANA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ZVRA vs SANA
ZVRA NASDAQ Head-to-Head Winner
Zevra Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$9.25
+1.87% 1D
Market Cap $540.3M
TTM Revenue $148M
Forward P/E 10.4x
Beta / 30D Vol 1.19β · 94% Vol
Unified Composite Score
49.4 / 100 HOLD
Tech 37.0 Fund 53.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.4%), weak momentum, RSI 39
RSI-14: 38.9 · SMA20: $10.53 · SMA50: $10.92
SANA NASDAQ
Sana Biotechnology, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.88
-6.93% 1D
Market Cap $605.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.82β · 78% Vol
Unified Composite Score
44.3 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 66.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.0%), weak momentum, RSI 31
RSI-14: 30.6 · SMA20: $2.37 · SMA50: $2.68

6-Pillar Scorecard Institutional Category Breakdown (ZVRA 5 – 1 SANA)

Columns: Metric · ZVRA · SANA
1. Valuation Multiples ZVRA
Forward P/E 10.4x N/M
Trailing P/E 7.4x N/M
PEG Ratio 10.67x N/M
EV / Revenue 2.8x N/M
2. Growth & Scale ZVRA
Revenue Growth (YoY) +44.9% +0.0%
Earnings Growth (YoY) -88.4% +0.0%
TTM Revenue (USD) $148M N/A
Market Cap $540.3M $605.3M
3. Profitability & Quality ZVRA
Gross Margin 95.4% N/A
Operating Margin 31.5% 0.0%
Net Profit Margin 52.8% 0.0%
Return on Equity (ROE) 41.9% -79.5%
4. Balance Sheet & Cash Flow ZVRA
Cash Generation (TTM) $38M -$145M
Cash Flow Margin 25.9% N/A
Net Cash / Leverage $121M Net Cash $13M Net Debt (0.30x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SANA
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 82.5% (18th %ile) 105.5% (4th %ile)
Put/Call OI Skew 1.62x (Put-Skewed) 0.61x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat ZVRA
OpEx & R&D Intensity 63.9% of Rev ($94M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ZVRA (8) vs SANA (2)
Institutional Metric ZVRA SANA Criterion Row Edge
Market Capitalization
Scale
$540.3M $605.3M Larger Scale SANA
Trailing P/E Ratio
Valuation
7.4x N/M Lower Multiple ZVRA
Forward P/E Ratio
Valuation
10.4x N/M Lower Multiple ZVRA
Revenue Growth (YoY)
Growth
+44.9% +0.0% Higher Growth ZVRA
Operating Margin (TTM)
Profitability
31.5% 0.0% Higher Margin ZVRA
Net Profit Margin
Profitability
52.8% 0.0% Higher Margin ZVRA
Return on Equity (ROE)
Capital Efficiency
41.9% -79.5% Higher ROE ZVRA
52-Week Range Position
Momentum
18% ($8–$15) 1% ($2–$5) Stronger Trend ZVRA
Beta / 30D Volatility
Risk Regime
1.19β · 94% Vol 1.82β · 78% Vol Lower Realized Risk SANA
Unified Institutional Score
Composite Signal
49.4 / 100 (HOLD) 44.3 / 100 (HOLD) Higher Composite ZVRA
Trailing 12M Revenue (USD)
Operating Scale
$148M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
95.4% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
10.67x PEG · 2.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$38M ($121M Net Cash) -$145M ($13M Net Debt (0.30x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ZVRA +10.24 pp
ZVRA: -6.94% · SANA: -17.18%
3M Horizon ZVRA +28.16 pp
ZVRA: -20.05% · SANA: -48.21%
6M Horizon ZVRA +26.85 pp
ZVRA: -11.31% · SANA: -38.16%
1Y Horizon ZVRA +48.85 pp
ZVRA: +0.22% · SANA: -48.63%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZVRA vs SANA. Trailing 12-month operating profitability (ZVRA 31.5% vs SANA 0.0%) and valuation multiples (ZVRA 10.4x vs SANA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ZVRA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$148M
Gross Margin95.4%
Op. Margin31.5%
ROE / Fwd P/E41.9% · 10.4x
SANA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-79.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ZVRA BREAKDOWN
111d in phase · OBV DISTRIBUTION
Current IV 82.5%
IV Percentile 18th %ile
Put/Call OI Skew 1.62x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact ZVRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SANA BREAKDOWN
57d in phase · OBV NEUTRAL
Current IV 105.5%
IV Percentile 4th %ile
Put/Call OI Skew 0.61x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SANA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ZVRA Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $540.3M market capitalization and 31.5% operating margin.
OpEx & R&D Reinvestment 63.9% of Rev ($94M)
90D Engineering Disclosures 0 Published
SANA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $605.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ZVRA vs SANA Key Questions & Quantitative Answers

As of Nov 16, 2026, Zevra Therapeutics, Inc. (ZVRA) is the stronger overall head-to-head candidate over Sana Biotechnology, Inc. (SANA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZVRA carries a Unified Composite Score of 49.4/100 (HOLD) at $9.25 (10.4x Forward P/E, 31.5% operating margin), whereas SANA carries 44.3/100 (HOLD) at $1.88 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: ZVRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.9); meanwhile SANA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ZVRA leads the Growth & Scale pillar: ZVRA posts +44.9% YoY revenue growth and -88.4% YoY earnings growth on $148M TTM revenue (95.4% gross margin, 31.5% operating margin), compared with SANA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ZVRA generates $148M in USD-normalized revenue versus N/A for SANA. In operating R&D and SG&A reinvestment, ZVRA deploys 63.9% of Rev ($94M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SANA.

ZVRA screens cheaper on headline valuation multiples. ZVRA trades at 10.4x Forward P/E, 7.4x Trailing P/E, 10.67x PEG, and 2.8x EV/Revenue (25.9% FCF margin), whereas SANA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZVRA (41.9% ROE) versus SANA (-79.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ZVRA carries 82.5% implied volatility (18th %ile, Compressed (<25th %ile)), a 1.62x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.19β · 94% Vol realized risk). By comparison, SANA carries 105.5% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.61x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.